Evidence map›Paper›PMID 40179276›Full record

ArticleBiochemistry2025

Inhibition by 4-(4-Bromo-2-oxo-3

Pawel Jaruga, Melis Kant, Michael M Luzadder, R Stephen Lloyd, Istvan Boldogh, Miral Dizdaroglu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pawel JarugaBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States.ORCID 0000-0001-9192-6084
Melis KantBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States.
Michael M LuzadderOregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, Oregon 97239, United States.ORCID 0000-0001-7227-6207
R Stephen LloydOregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, Oregon 97239, United States.ORCID 0000-0001-7273-372X
Istvan BoldoghDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas 77555, United States.ORCID 0000-0002-0088-1130
Miral DizdarogluBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States.ORCID 0000-0003-0283-1695

Funding

Virus, Tissue Culture and ImmunoassayP01AI062885 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI BOLDOGH, ISTVAN STEVEN · 2005 to 2022
$23.9M
Targeting DNA Base Excision Repair in Acute Myeloid LeukemiasR21CA216551 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LLOYD, R. STEPHEN · 2017 to 2018
$368k
NCI NIH HHS R21 CA216551NIAID NIH HHS P01 AI062885
6 · The paper itself

Abstract

DNA glycosylases of the base excision repair pathway have become clinically validated drug targets for the treatment of several diseases. Human OGG1 (hOGG1) is specific for the removal of the highly mutagenic 8-oxoguanine (8-oxo-Gua) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua) from damaged DNA. To develop clinically approved drugs, various small-molecule inhibitors of hOGG1 have been developed to inhibit its glycosylase and lyase activities, with 4-(4-bromo-2-oxo-3H-benzimidazol-1-yl)-

Indexed as

BenzimidazolesDNA DamageDNA GlycosylasesEnzyme InhibitorsGuaninePiperidinesPyrimidinesDNA RepairHumans2,6-diamino-4-hydroxy-5-formamidopyrimidine8-hydroxyguanineBenzimidazolesDNA GlycosylasesEnzyme InhibitorsGuanineoxoguanine glycosylase 1, humanPiperidinesPyrimidines

Identifiers

PMID40179276
PMCPMC12004446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.